Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
0.9259
-0.0147 (-1.56%)
At close: Jul 24, 2026, 4:00 PM EDT
0.9190
-0.0069 (-0.75%)
After-hours: Jul 24, 2026, 7:58 PM EDT
Tempest Therapeutics Employees
Tempest Therapeutics had 5 employees as of March 31, 2026. The number of employees increased by 1 or 25.00% since the number was last reported on December 31, 2025.
Employees
5
Change
1
Growth
25.00%
Revenue / Employee
n/a
Profits / Employee
-$8,619,600
Market Cap
13.71M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 5 | 1 | 25.00% |
| Dec 31, 2025 | 4 | -20 | -83.33% |
| Dec 31, 2024 | 24 | 7 | 41.18% |
| Dec 31, 2023 | 17 | -2 | -10.53% |
| Dec 31, 2022 | 19 | 2 | 11.76% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| NextCure | 40 |
| Senti Biosciences Holdings | 39 |
| BioLineRx | 24 |
| Citius Pharmaceuticals | 23 |
| OSR Health | 22 |
| SeaStar Medical Holding | 17 |
| Cocrystal Pharma | 10 |
| Lexaria Bioscience | 7 |
TPST News
- 4 days ago - Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T - GlobeNewsWire
- 8 days ago - Tempest Therapeutics Proxy statement: Proxy filing - Filings
- 10 days ago - Tempest Therapeutics Slides: Corporate presentation - Filings
- 10 days ago - Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026 - GlobeNewsWire
- 18 days ago - Tempest Therapeutics Proxy statement: Proxy filing - Filings
- 4 weeks ago - Tempest Therapeutics registers to sell 2.43M shares of common stock for holders - TheFly
- 4 weeks ago - Tempest Therapeutics Registration statement: Registration filing - Filings
- 6 weeks ago - Tempest Therapeutics Proxy statement: Proxy filing - Filings